Questcor stock swells on Novartis drug Synacthen (tetracosactide) buy

New Drug Approvals



Synacthen (tetracosactide)

Questcor’s stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis’ rival immune drug Synacthen.

The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) and Synacthen Depot in its domestic market, and potentially some other regions (subject to  closing conditions).

read all at

Tetracosactide (marketed under the brand name Synacthen) is a synthetic analogue consisting of the first 24 amino acids of the naturally occurring adrenocorticotrophic hormone (ACTH). It is known to be used as a doping agent to increase the secretion of glucocorticoids by adrenal glands.


View original post


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s